Acronyms
Immune System
MAbs
RSV
Beyfortus
100

RSV

Respiratory Syncytial Virus

100

Which cell type leads to antibody creation?

B-Cells lead to antibody creation, which is the connection to vaccines and MAbs

100

What is used to manufacture MAbs?

living cells

100

What is the leading cause of lower respiratory tract infections in infants?

RSV

100

What is the non-branded name for Beyfortus?

nirsevimab

200

MAb

monoclonal antibody

200

Microorganisms that cause infection

pathogens

200

Is protection slow or rapid?

Rapid.
200

Is RSV circulation annual or seasonal?

RSV circulates seasonally
200

Nirsevimab does not prevent RSV in the nose. What does it do?

It stops RSV progression to the lungs, which is where serious lower respiratory infections occur.

300

MOA

mechanism of action

300

Any substance recognized which induces an immune response

antigen

300

True of False: All vaccinations are immunizations and all immunizations are vaccinations?

FALSE - It's important to refer to MAbs as immunizations and not vaccinations

300

Which protein fuses virus to a cell?

pre-fusion F protein

300

Nirsevimab provides protection for about ____ months, which is about the typical length of what?

5 months + RSV season

400

LRTI

Lower respiratory tract infection

400

2 main types of lymphocytes

T-Cells (T-Lymphocytes) and B-Cells (B-T-Lymphocytes)

400

_______ provide active immunity whereas MAbs provide _____ immunity. 

Vaccines + Passive

400

RSV infection starts in the _____ and progresses to the _____.

Nose + Lungs

400

Which of the following statements is true of Nirsevimab?

1. It targets G protein

2. It stops progression of RSV

3. It prevents RSV

4. It targets pre-fusion F protein

2 + 4: Nirsevimab targets the pre-fusion F protein to stop the progression of RSV. 

500

VFC

Vaccines for Children

500

Define passive immunity

When the body receives antibodies rather than makes them. It can occur naturally from pregnant person to fetus or through provision of antibody products like IGGs and MAbs. 

500

Typical length of time for protection with a standard MAb vs. a longer-acting MAb?

1 month vs. 5 months

500

Infants under 12 months of age are more likely to develop severe RSV disease than adults or toddlers/children. This is partly because their immune system is ___  ______.

less developed - and their lungs contain very small and fragile airways that can easily be obstructed by inflammation and fluid build-up.

500

When was Beyfortus approved by the FDA in the United States?

July 17th, 2023

M
e
n
u